By using foundation models to analyze vast datasets, companies can create a synthetic 'standard of care' arm for single-arm Phase 1 trials. The AI matches patients based on deep clinical and genomic parameters, providing insights comparable to a much larger Phase 3 trial.

Apply financial forecasting techniques to large patient databases. By treating individual patient data points like historical stock prices, researchers can build complex regression models to project future health outcomes, an innovative approach that earns recognition from national medical academies.

General large language models trained on internet data lack life sciences patterns, resulting in low accuracy when forecasting clinical trial success. Post-training models on millions of longitudinal patient records and historical trials enables accurate predictions of medical outcomes and adverse events.

By modeling a complete patient trajectory using multi-omics data, AI could predict how a patient would fare on a placebo or standard care. This would allow for "synthetic" control arms, reducing the ethical and practical challenges of enrolling patients in non-treatment groups.

The convergence of AI, massive health datasets, and genomics is creating a new paradigm in medicine. Instead of lengthy human trials, AI will prove drug solutions and create personalized therapeutics by analyzing an individual's condition against millions of data points, dramatically accelerating medical breakthroughs.

While molecular foundation models optimize drug candidates in silico, they cannot foresee human clinical outcomes. By running protocol criteria against cohorts of simulated real-world patients, study teams can forecast average endpoint effects and adverse event probabilities before enrolling patients.

The ultimate goal of a connected patient data ecosystem is to shift from reactive support to genuinely anticipatory care. In the near future, AI agents will sense and predict risks—like non-adherence or access barriers—and trigger interventions before the patient or their physician even encounters the problem.

Early efforts like the Human Cell Atlas were criticized as mere data collection ("stamp collecting"). However, the rise of LLMs provided the key to unlock this data's value, transforming vast, unstructured biological datasets into systems that generate scientific insights and move biology from discovery to engineering.

The next frontier in preclinical research involves feeding multi-omics and spatial data from complex 3D cell models into AI algorithms. This synergy will enable a crucial shift from merely observing biological phenomena to accurately predicting therapeutic outcomes and patient responses.